Trading and business update

Cambridge, UK, 21 February 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides the following business update for the period to 20 February 2017. Highlights Group revenue for the full year expected to be in line with […] Read more

Antibody manufacturing development agreement signed with UCL

Cambridge, UK, 21 February 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a manufacturing agreement with University College London (‘UCL’), one of the world’s leading universities. Under the agreement, Abzena will manufacture Magacizumab, an […] Read more

Abzena Signs New ThioBridge License Agreement

Cambridge, UK, 20 January 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement with a San Diego-based biopharmaceutical company for Abzena’s novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology. ThioBridge™ links […] Read more

Licence agreement for Composite Human Antibody™ technology

Cambridge, UK, 22 December 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Trieza Therapeutics, Inc (‘Trieza’). Trieza is a start-up biotechnology company specialising in the discovery and development of immunomodulatory […] Read more

Half year results: Integrated service offering driving revenue growth

Cambridge, UK, 30 November 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2016. Highlights Group revenue up 157% to £9.0 million (H1 2016: £3.5 million) […] Read more

‘Abzena inside’ product clinical study data to be presented at upcoming conference

Cambridge, UK, 23 November 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that Opsona Therapeutics Ltd (‘Opsona’) has announced that preliminary results from its ongoing Phase I/II study of ‘Abzena inside’ product OPN-305 in second line […] Read more

Licensed product candidate update

Cambridge, UK, 2 November 2016 – Abzena plc (AIM: ABZA, ‘Abzena’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that during the conference call to accompany Gilead Sciences Inc.’s (Gilead) announcement of third quarter earnings on 1 November 2016, Gilead stated that no further development of […] Read more

Abzena makes two senior executive appointments to drive growth of international business

Cambridge, UK, 24 October 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces that John Manzello and Sven Lee have taken up senior executive appointments with Abzena in the US as President, Abzena US and Chief […] Read more

Licensed product candidate update

Cambridge, UK, 21 October 2016 – Abzena plc (AIM: ABZA, ‘Abzena’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that Gilead Sciences, Inc. has announced top line Phase II clinical study results of its product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, […] Read more

Licensed product candidate update

Cambridge, UK, 22 September 2016 – Abzena plc (AIM:ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that Gilead Sciences, Inc. (Nasdaq:GILD, ‘Gilead’) has announced that it is stopping its Phase II/III clinical study of GS-5745 in patients with ulcerative colitis. The […] Read more

Interested in our services? Get In Touch